PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 117655

[Immunostimulating activity of the lipopolysaccharides of blue-green algae].

N N Besednova·T P Smolina·L V Mikheĭskaia·R G Ovodova
View original source ↗Export metadata ↓

Abstract

The whole cells of blue-gree algae and lipopolysaccharides isolated from these cells were shown to stimulate the production of macro-(mainly) and microglobulin antibodies in rabbits. The macro- and microphage indices in rabbits increased significantly after the injection of LPS isolated from blue-green algae 24--48 hours before infecting the animals with a virulent Y. pseudotuberculosis strain. Besides, the inhibiting action of this strain on the migration of phagocytes to the site of infection was abolished immediately after the injection. The use of the indirect hemagglutination test allowed to prove the absence of close antigenic interrelations between blue-green algae and the following organisms: Spirulina platensis, Microcystis aeruginosa, Phormidium africanum and P. uncinatum.

Explore related subjects

Adjuvants, ImmunologicAnimalsAntigensCyanobacteriaHemagglutination TestsImmunizationLipopolysaccharidesMicePhagocytosisRabbitsTime FactorsYersiniaYersinia pseudotuberculosis InfectionsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N N Besednova, T P Smolina, L V Mikheĭskaia, R G Ovodova. 1979. [Immunostimulating activity of the lipopolysaccharides of blue-green algae].. https://pubmed.ncbi.nlm.nih.gov/117655/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1979

Active, specific immunotherapy of murine leukemia. II. Adjuvant effect of Corynebacterium parvum.

We have previously shown that irradiated LSTRA cells (LX) were immunogenic and could prolong survival of mice bearing LSTRA tumors. This study demonstrated that addition of Corynebacterium parvum to the LX dramatically improved the strength of tumor immunity. In pretreatment-challenge experiments, C. parvum augmented the immunogenicity of 10(6) LX given intradermally, with an optimum dose of 0.14-1.4 microgram C. parvum per mouse. In therapy experiments (intraperitoneal vaccine treatment after tumor cell challenge), the therapeutic effect of 10(7) LX was improved by admixture of C. parvum, leading to a larger number of cured mice, permitting treatment of a larger challenge inoculum, and allowing later initiation of treatment than was possible with LX alone. Optimal dose of C. parvum for therapy was 1,400 microgram per mouse. Presensitization to C. parvum or use of repeated vaccine injections did not further improve the therapeutic effect. Cure of tumor-bearing mice by the mixed vaccine was tumor-specific. These results suggest that C. parvum is a potent adjuvant for use in active, tumor-specific immunotherapy.

Adjuvants, Immunologic↗
PubMed1979

Augmentation of natural killer activity by pyran copolymer in mice.

Treatment of older mice with pyran copolymer, a known interferon-inducer, was found to result in a rapid boosting of cell-mediated cytolytic activity against YAC-1 tumor target cells. The effector cells were characterized as being non-adherent and were presumed to be natural killer (NK) cells. Augmentation occurred in various lymphoid organs and was detectable 2-3 days after drug treatment. Differences in the levels of boosted activity among the lymphoid organs resulted when the route of administration was varied. The degree of augmentation was largely independent of the dose of pyran, but did vary among different strains of mice. Augmentation, moreover, was followed by a rapid decline by 5-7 days.

Adjuvants, Immunologic↗